Trial Profile

Immediate versus delayed treatment with azathioprine or rituximab in anti-myelin oligodendrocytes glycoprotein (anti-MOG) antibodies associated acute demyelinating syndromes in children: a randomized controlled clinical trial

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Azathioprine (Primary) ; Rituximab (Primary) ; Methylprednisolone; Prednisolone
Indications Demyelinating disorders; Optic neuritis; Transverse myelitis
Focus Therapeutic Use
Acronyms IDAR

07 Apr 2025 Planned End Date changed from 1 Aug 2029 to 1 Apr 2030.
07 Apr 2025 Planned primary completion date changed from 1 Jan 2026 to 1 Apr 2027.
07 Apr 2025 Planned initiation date changed from 1 Jan 2024 to 1 Apr 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com